mixedAnecdotalMar 12, 2026
Self-reported side effects
Large-scale Reddit analysis is being used to surface semaglutide side-effect themes that may deserve comparison with labels and trials.
arXivmedium confidencepreprint
Source Semaglutide
Ozempic · Wegovy · Rybelsus
Weight LossApprovedApprovedPrescriptionSubQOral
Popular for:Weight loss, type 2 diabetes, cardiovascular risk reduction
686
Registered Trials
284
Trial Publications
4,535
PubMed References
Approved
Evidence Level
Overview
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. The short version: people usually care about it for weight loss, type 2 diabetes, cardiovascular risk reduction, but the strength of the evidence depends heavily on indication and study type.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. It is arguably the most impactful obesity drug ever developed, marketed as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral form for diabetes). It sparked the modern GLP-1 weight loss revolution and is one of the best-selling drugs in history.
**Originally developed for: **Type 2 diabetes glycemic control (Ozempic, FDA approved December 2017). Subsequently developed for chronic weight management (Wegovy, FDA approved June 2021). Now being studied for cardiovascular risk reduction, NASH, Alzheimer's, and addiction.
Research Snapshot
What the evidence says
ApprovedSemaglutide currently shows 686 registered trials from ClinicalTrials.gov, 284 PubMed trial publications (261 RCT-tagged), and 4,535 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 686 registered trials are tracked from ClinicalTrials.gov intervention records.
- 284 PubMed clinical-trial publications are indexed.
- 261 PubMed randomized controlled trial publications are indexed.
- 4,535 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
Semaglutide mimics natural GLP-1 hormone.
Key Research Benefits
Primary Benefits:
Significant weight loss — ~15% average at 2.4 mg (STEP trials, NEJM 2021)
Glycemic control — HbA1c reductions of 1.5-1.8% (SUSTAIN trials)
Cardiovascular risk reduction — SELECT trial: 20% reduction in MACE (heart attack, stroke, CV death) in overweight/obese adults
Secondary/Emerging Benefits:
Kidney protection — FLOW trial showed 24% reduction in kidney disease progression
NASH/MASLD improvement — liver fat reduction in studies
Addiction reduction — emerging research suggests reduced alcohol, nicotine, and other substance cravings
Alzheimer's disease — clinical trials underway
Clinical Evidence Summary
Research Pipeline
Preclinical
Animal
Phase I
Phase II
Phase III
Approved
686
Registered Trials
284
Trial Publications
261
RCT Publications
4,535
PubMed References
ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
686
Registered trials
284
Trial publications
261
RCT publications
4,535
PubMed references
1,278
Reviews
240
Meta-analyses
Registered trials source
Jun 1, 2026
Semaglutide
Uses the exact compound name as a ClinicalTrials.gov intervention query.
View source- STEP trials (1-5) — Phase 3 obesity program. STEP-1 (NEJM, 2021): 14.9% weight loss at 68 weeks with 2.4 mg.
- SUSTAIN trials (1-10) — Phase 3 diabetes program. Comprehensive data on glycemic control.
- SELECT trial (NEJM, 2023) — 17,604 participants. 20% reduction in major adverse cardiovascular events. Led to expanded FDA indication for CV risk reduction.
- FLOW trial — 24% reduction in kidney disease progression. Led to expanded indication for chronic kidney disease.
> Clinical trial status: FDA APPROVED for multiple indications. One of the most extensively studied drugs in recent history with 50,000+ patients in clinical trials. Active research continues for Alzheimer's, NASH, addiction, heart failure, and more.
Key PubMed References
4,535 PubMed references · showing top 25 by relevance
View all on PubMedSemaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
Human Study
Krüger N, Schneeweiss S, Fuse K, et al. · JAMA · 2025
PMID: 40886075Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Meta-Analysis
Karagiannis T, Malandris K, Avgerinos I, et al. · Diabetologia · 2024
PMID: 38613667A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
Meta-Analysis
Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024
PMID: 38629387Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
Human Study
Hathaway JT, Shah MP, Hathaway DB, et al. · JAMA ophthalmology · 2024
PMID: 38958939Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Human Study
Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024
PMID: 38740993Anecdotes & Sentiment
Public discussion, not clinical evidence
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
mixedAnecdotalFeb 24, 2026
Semaglutide versus tirzepatide debate
Community comparison threads often focus on whether higher-dose semaglutide can narrow the perceived gap with tirzepatide.
Reddit / r/GLP1ResearchTalklow confidencereddit
Source Side Effects & Safety
**Common Side Effects:** - Nausea (~20-44% in trials, usually decreases over time) - Diarrhea (~15-30%) - Vomiting (~5-24%) - Constipation - Headache, fatigue **Rare but Serious Risks:** - Pancreatitis - Thyroid C-cell tumors (boxed warning) - Gallbladder disease - Muscle mass loss without exercise — important to maintain resistance training - "Ozempic face" — facial volume loss from rapid fat loss > Boxed Warning: Thyroid C-cell tumors in rodents.
Common Side Effects:
Nausea (~20-44% in trials, usually decreases over time)
Diarrhea (~15-30%)
Vomiting (~5-24%)
Constipation
Headache, fatigue
Rare but Serious Risks:
Pancreatitis
Thyroid C-cell tumors (boxed warning)
Gallbladder disease
Muscle mass loss without exercise — important to maintain resistance training
"Ozempic face" — facial volume loss from rapid fat loss
> Boxed Warning: Thyroid C-cell tumors in rodents. Contraindicated in MTC/MEN2 history. Not for type 1 diabetes. Caution with pancreatitis history. Important: ~2/3 of weight is regained within 1 year of stopping. Long-term or indefinite use may be necessary.
Known Interactions
No curated interaction entry is live for Semaglutide yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.